Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evaluation Of Drug Benefits Needs Quantitative Measures, FDA's Graham Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Evidence-based standards currently applied to risk should be applied to benefit, the FDAer adds.

You may also be interested in...



Drug Risks And Benefits Should Be Quantified For Public, Pfizer Exec Says

Industry will collaborate with FDA on ways to communicate risk/benefit information to patients, physicians and lawmakers, Pfizer Senior VP Corr says.

Serevent, Advair, Foradil Withdrawals To Be Considered By Advisory Committee

FDA's Pulmonary-Allergy Drugs Advisory Committee will vote July 13 whether currently available data support continued marketing of the long-acting beta-agonist bronchodilators. Committee will also consider labeling changes for formoterol concerning severe asthma exacerbations.

NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter

DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel